Entrada Therapeutics, Inc. (TRDA): who owns it and who trades it
As of Nov 16, 2026, TRDA insiders reported 26 open-market sales worth $6.7M and 5 purchases worth $291K in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was MPM BioVentures 2018 GP LLC (10% owner), with $1.9M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Entrada Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TRDA
129 funds and institutions reported TRDA shares worth $219M at the end of Q2 2026, about 76% of the company. The largest holder is Baker Bros. Advisors LP with 13.1%.
Funds and institutions (13F) 76%Everyone else 24%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 5.07M | 13.07% | $37.3M | No change |
| 5AM Venture Management, LLC | 4.06M | 10.45% | $29.9M | No change |
| BlackRock, Inc. | 2.58M | 6.65% | $19M | +10% |
| Merck & Co., Inc. | 1.74M | 4.48% | $12.8M | – |
| Vanguard Capital Management LLC | 1.27M | 3.27% | $9.3M | +1% |
| Mpm Bioimpact LLC | 1.25M | 3.23% | $9.2M | – |
| TCG Crossover Management, LLC | 1.06M | 2.73% | $7.8M | -54% |
| Wellington Management Group LLP | 954,419 | 2.46% | $7M | -8% |
| Millennium Management LLC | 763,959 | 1.97% | $5.6M | +47% |
| StepStone Group LP | 761,277 | 1.96% | $5.6M | No change |
| Geode Capital Management, LLC | 717,430 | 1.85% | $5.3M | +8% |
| AQR Capital Management LLC | 699,537 | 1.80% | $5.1M | +780% |
| Nantahala Capital Management, LLC | 601,150 | 1.55% | $4.4M | +277% |
| State Street Corp | 596,677 | 1.54% | $4.4M | +12% |
| T. Rowe Price Associates | 542,316 | 1.40% | $4M | +3% |
| JPMorgan Chase & Co | 496,457 | 1.28% | $3.8M | – |
| Acadian Asset Management LLC | 400,862 | 1.03% | $2.9M | +20% |
| Citadel Advisors LLC | 394,323 | 1.02% | $2.9M | +83% |
| Dimensional Fund Advisors LP | 376,136 | 0.97% | $2.8M | +16% |
| Northern Trust Corp | 309,942 | 0.80% | $2.3M | +32% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TRDA insiders reported $291K of open-market purchases and $6.7M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | MPM BioVentures 2018 GP LLC +2 | 10% owner | Sale | 28,837 | $7.13 | $206K | Form 4 |
| Sep 8, 2026 | MPM BioVentures 2018 GP LLC +2 | 10% owner | Sale | 192,500 | $7.41 | $1.4M | Form 4 |
| Sep 4, 2026 | MPM BioVentures 2018 GP LLC +2 | 10% owner | Sale | 38,500 | $7.11 | $274K | Form 4 |
| Sep 3, 2026 | MPM BioVentures 2018 LLC +2 | 10% owner | Sale | 32,263 | $7.17 | $231K | Form 4 |
| Sep 2, 2026 | MPM BioVentures 2018 LLC +2 | 10% owner | Sale | 25,131 | $7.19 | $181K | Form 4 |
| Sep 1, 2026 | MPM BioVentures 2018 LLC +2 | 10% owner | Sale | 29,088 | $7.06 | $205K | Form 4 |
| Aug 31, 2026 | MPM BioVentures 2018 LLC +2 | 10% owner | Sale | 44,259 | $6.99 | $309K | Form 4 |
| Aug 28, 2026 | MPM BioVentures 2018 LLC +2 | 10% owner | Sale | 3,733 | $7.01 | $26.2K | Form 4 |
| Aug 27, 2026 | MPM BioVentures 2018 LLC +2 | 10% owner | Sale | 38,922 | $7.20 | $280K | Form 4 |
| Aug 26, 2026 | Todd Foley +9 | 10% owner | Sale | 14,569 | $7.06 | $103K | Form 4 |
| Aug 25, 2026 | Todd Foley +9 | 10% owner | Sale | 26,522 | $7.54 | $200K | Form 4 |
| Aug 24, 2026 | Todd Foley +9 | 10% owner | Sale | 21,623 | $7.34 | $159K | Form 4 |
| Aug 10, 2026 | Kush Parmar | Director | Sale | 92,444 | $7.00 | $647K | Form 4 |
| Aug 7, 2026 | Kush Parmar | Director | Sale | 52,317 | $6.85 | $358K | Form 4 |
| Aug 6, 2026 | Kush Parmar | Director | Sale | 10,494 | $7.00 | $73.5K | Form 4 |
| Jul 31, 2026 | Scott M Rocklage +5 | 10% owner | Sale | 1,718 | $6.85 | $11.8K | Form 4 |
| Jul 30, 2026 | Scott M Rocklage +5 | 10% owner | Sale | 114,756 | $6.93 | $795K | Form 4 |
| May 20, 2026 | Bernhardt G Zeiher | Director | Purchase | 5,000 | $5.86 | $29.3K | Form 4 |
| May 4, 2026 | Natarajan Sethuraman | President | Sale plan | 25,907 | $15.39 | $399K | Form 4 |
| May 4, 2026 | Nathan J Dowden | President | Sale plan | 15,000 | $15.33 | $230K | Form 4 |
| Apr 1, 2026 | Kory James Wentworth | CFO | Sale plan | 2,500 | $12.95 | $32.4K | Form 4 |
| Mar 10, 2026 | Nathan J Dowden | President | Sale plan | 11,894 | $13.05 | $155K | Form 4 |
| Mar 10, 2026 | Kory James Wentworth | CFO | Sale plan | 11,388 | $13.02 | $148K | Form 4 |
| Mar 9, 2026 | Nathan J Dowden | President | Sale plan | 3,116 | $13.02 | $40.6K | Form 4 |
| Mar 9, 2026 | Kory James Wentworth | CFO | Sale plan | 5,089 | $13.00 | $66.2K | Form 4 |
| Mar 4, 2026 | Kory James Wentworth | CFO | Sale plan | 7,988 | $12.25 | $97.9K | Form 4 |
| Nov 21, 2025 | Kory James Wentworth | CFO | Sale plan | 8,910 | $9.98 | $88.9K | Form 4 |
| Nov 20, 2025 | Felix Baker +3 | 10% owner | Purchase | 13,082 | $9.07 | $119K | Form 4 |
| Nov 20, 2025 | Felix Baker +3 | 10% owner | Purchase | 1,186 | $9.07 | $10.8K | Form 4 |
| Nov 20, 2025 | Felix Baker +3 | 10% owner | Purchase | 13,386 | $9.07 | $121K | Form 4 |
| Nov 20, 2025 | Felix Baker +3 | 10% owner | Purchase | 1,213 | $9.07 | $11K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| MPM BioVentures 2018 GP LLC | 10% owner | – | $1.9M | Sep 9, 2026 |
| MPM BioVentures 2018 LLC | 10% owner | – | $1.2M | Sep 3, 2026 |
| Kush Parmar | Director | – | $1.1M | Aug 10, 2026 |
| Scott M Rocklage | 10% owner | – | $807K | Jul 31, 2026 |
| Todd Foley | 10% owner | – | $462K | Aug 26, 2026 |
| Kory James Wentworth | Chief Financial Officer | – | $434K | Apr 1, 2026 |
| Nathan J Dowden | President & COO | – | $426K | May 4, 2026 |
| Natarajan Sethuraman | President, Research & Develop. | – | $399K | May 4, 2026 |
| Felix Baker | 10% owner | $262K | – | Nov 20, 2025 |
| Bernhardt G Zeiher | Director | $29.3K | – | May 20, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TRDA short interest
Moderate short interest. 7.2% of TRDA shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 86%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.81M TRDA shares were sold short, 7.2% of the shares outstanding, down 14.2% from the report before. At the average daily volume of 408,246 shares, buying them all back would take about 6.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.81M | 7.21% | -14% | 408,246 | 6.9 |
| Oct 15, 2026 | 3.27M | 8.40% | +9% | 380,605 | 8.6 |
| Sep 30, 2026 | 2.99M | 7.68% | +9% | 303,169 | 9.9 |
| Sep 15, 2026 | 2.74M | 7.05% | +17% | 340,415 | 8.1 |
| Aug 31, 2026 | 2.35M | 6.02% | -1% | 219,451 | 10.7 |
| Aug 14, 2026 | 2.37M | 6.08% | +10% | 384,854 | 6.2 |
| Jul 31, 2026 | 2.14M | 5.51% | -4% | 494,747 | 4.3 |
| Jul 15, 2026 | 2.23M | 5.75% | +6% | 356,582 | 6.3 |
| Jun 30, 2026 | 2.11M | 5.44% | +10% | 360,809 | 5.8 |
| Jun 15, 2026 | 1.91M | 4.93% | +11% | 239,128 | 8.0 |
| May 29, 2026 | 1.73M | 4.45% | +15% | 386,626 | 4.5 |
| May 15, 2026 | 1.51M | 3.88% | +51% | 972,065 | 1.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Entrada Therapeutics company events
Entrada Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 14, 2026AnnouncementThe Company announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 10, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
- May 19, 2026AnnouncementShared information with investors. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementThe Company reported its progress across its portfolio of RNA-based therapeutics for the treatment of neuromuscular and ocular diseases. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Entrada Therapeutics financials
Famous investors that hold TRDA
4 of the 50 well-known investors we track reported holding TRDA in their latest 13F filing. The largest position is Ken Griffin's, worth $2.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 461,737 | $2.9M | 0.0% | +17% |
| Israel Englander · Millennium Management | Q3 2026 | 344,603 | $2.2M | 0.0% | -55% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 199,200 | $1.3M | 0.0% | +4% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 101,727 | $646K | 0.0% | +257% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Entrada Therapeutics, Inc. (TRDA) stock
Who owns the most TRDA stock?
The largest reported owner of Entrada Therapeutics, Inc. (TRDA) is Baker Bros. Advisors LP, with 13.1% of the company. In total, 129 funds and institutions reported holding TRDA at the end of Q2 2026, together about 76% of the shares. See the largest owners.
Are TRDA insiders buying or selling?
In the last 12 months, TRDA insiders reported 5 open-market purchases worth $291K and 26 sales worth $6.7M. The latest trade was on Sep 9, 2026. See every trade.
What is the short interest in TRDA?
As of Oct 30, 2026, 2.81M TRDA shares were sold short, 7.2% of the shares outstanding, down 14.2% from the report before. At the average daily volume of 408,246 shares, buying them all back would take about 6.9 trading days (days to cover). See the history.
Which famous investors hold TRDA?
4 of the 50 well-known investors we track reported TRDA in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $2.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.